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Tuberculosis (TB),or consumption, is caused by the bacterium Mycobacterium tuberculosis (MTB). TB has existed since ancient times and still continues to be a significant global health problem. It is one of the top ten causes of death worldwide and affects approximately 10 million people each year. The World Health Organization (WHO) identifies it as the leading cause of mortality from a single infectious agent, topping HIV/AIDS, with 1.3 million deaths in 2017.2 It has been declared a global health emergency, and efforts for prevention and disease eradication continue to be of the utmost importance in achieving better health outcomes for the world.
2.0 	BACKGROUND
Tuberculosis mainly affects the lungs, but infection can also be presented in other parts of the body. 1TB appears in two forms: active and latent. 3 Most TB infections are latent and do not have symptoms. Active TB results in cough, fever, and weight loss. Active TB can also infect other organs, which can worsen disease outcome. Tuberculosis is transmitted through the air, when aerosol droplets expelled from the lungs of people with active TB spread to infect others.3 Active TB is diagnosed based on chest X-rays, microbiology tests such as molecular assays, and tuberculin skin test (TST). 4
Primary prevention of TB relies on childhood vaccination with the bacillus Calmette- Guerin (BCG) vaccine.4 The disease is treatable with multiple antibiotics over a long duration of time and a cure contingent on strict adherence to treatment. Growing antibiotic resistance in multiple-drug resistant (MTB) is an alarming problem in disease transmission and increasing mortality as it poses significant hurdles to prevention, patient care and, disease outcomes. 2
Recently, the emergence of MDR-TB, classified as being resistant to first-line TB drugs isoniazid (INH) and rifampicin (RIF) and extensively drug resistant tuberculosis (XDR-TB), has alarmed public health officials as it significantly hampers effective TB control. 2 MDR and XDR-TB cases present a significant infectious disease burden in developing countries as they require a substantially longer time to treat than drug-susceptible TB.2  Furthermore, they entail the need for second-line injectable anti-TB drugs, which are more expensive, have greater side effects and require a more intense regimen of patient observation. 2
2.1	MYCOBACTERIUM TUBERCULOSIS BACTERIOLOGY
TB infection in humans is caused by the species Mycobacterium tuberculosis (Mtb) belonging to the Mycobacteriaceae family.5 With a genome around 4 Mbp, it emerged as a human pathogen 70,000 years ago in Africa and spread worldwide following human migration.5 Gram staining, a method used to classify bacterial species into two distinctive groups, does not work for Mtb due to the presence of mycolic acid on its cell surface that causes it to appear either Gram-positive or Gram-negative.5 Microbiological detection of Mtb is done by Acid-fast stains or fluorescent stains.5 It is an aerobic, slow-growing organism with a doubling time of 12-24 hours under optimal conditions.5 Mycobacteria possess a unique cell wall that is thought to increase its virulence as it is impermeable to most compounds and drugs.5  Mycobacteria also have an outer membrane, which consists of an asymmetric lipid bilayer comprised of long fatty acids in the inner leaflet of mycolic acids.5 The outer leaflet is comprised of glycolipids to create a waxy cell surface. Together these form a periplasmic space, comprised of a thin layer of peptidoglycan covalently linked to arabinogalactan and lipoarabinomannan, which are then bound to mycolic acids. 5
Mtb has five type 7 (ESX1-5) protein secretion systems, which are the main virulence factors for infection.5 The most important secretion system is ESX1 required for translocation from the phagosome into the cytosol of infected macrophages. The lack of ESX1 in the attenuated BCG vaccine highlights its importance for the virulence of Mtb.5
Latent TB distinguishes itself by the presence of the dormancy survival regulon (DOS), which are a group of proteins that initiate a hypoxic response in harsh environments.5 The bacteria then stop replicating and activate anaerobic metabolism, which results in a dormant state. As a result, these dormant bacilli can stay for a long duration of time in vivo. If environmental conditions change for the better, a complex of resuscitating promoting factors (rpf) can act to trigger a cascade of events that eventually restart bacterial growth.5
Mtb bacteriology has important clinical implications as the bacilli are susceptible to antibiotic drugs at specific stages in their life cycle.5 For example, dormant bacteria are susceptible to pyraziniamide, rifampin, and metronidazole, but resistant to isoniazid.5 Meanwhile, spontaneous mutations in genes can trigger changes in amino acids and beta subunits of the bacteria’s RNA polymerase, which are a target for first-line TB drugs.5 A third mechanism of resistance is thought to be efflux pump systems, which can pump out drug molecules.6  They highlight the importance of prescribing the correct therapy followed by strict compliance as any missteps can increase genetic mutations that may lead to drug resistance.6
2.2	TB PATHOGENESIS
Most TB infections occur when Mtb enters the alveolar passages of humans in the form of an aerosol droplet. Alveolar macrophages, part of the innate immune system, are the first line of defense against Mtb invasion.7, 8 The macrophage phagocytizes, or engulfs, the bacterium and envelops it in a phagosome, which then combines with a lysosome, a membrane bound organelle, to create a phagolysosome which would normally then initiate a process to kill the bacterium.5 However, the unique properties of mycolic acids present on the bacterial cell surface aid in protecting the bacteria against any toxic substances the phagolysosome might secrete.5 The bacilli are then free to start replicating in alveolar macrophages and begin to diffuse to epithelial and endothelial cells. Mtb is also able to diffuse to other organs by using the lymphatic system.7 
The immunological response to TB infection is characterized by inflammation where macrophages, T lymphocytes and B lymphocytes aggregate to form a granuloma in the alveolar lumen. Calcification of the granuloma creates a lesion termed the Ghon complex, which causes the bacilli to be trapped inside it.7 The bacilli then persist inside these lesions and become dormant. This is defined as latent infection and is presented in over 90% of TB infections in humans.6 
Active infection occurs when the host immune response is unable to control bacterial infection and the bacteria enter the blood stream from the site of the damaged tissue, migrate to other parts of the body and appear as white tubercules.6 They can cause scarring in the tissues that leads to cavities filled with living bacteria. If the cavities connect to the bronchi, it causes the bacteria to be coughed out and spread.6 In short, TB disease is characterized by infection in the lungs is denoted as Pulmonary TB (PTB), which occurs in the majority of cases. Extrapulmonary TB (ETPB) occurs when the bacteria migrate to other organs of the body. ETPB can lead to other forms of TB depending on which site it infects. If TB is widely disseminated to several parts of the body, it can cause severe disease and is often fatal if untreated. This form of TB is known as miliary TB, and occurs in 10% of ETPB infections.7
2.3	EPIDEMIOLOGY
Significant disparities exist in who TB affects.2 The risk of contracting TB is higher in people who smoke and those with HIV/ AIDS, with over 350 000 HIV-related TB deaths among adults over 15. Further disparities exist when stratified by age and gender.2 Men have a significantly higher risk of infection and death from TB than women. In 2017, almost six million adult men were infected with TB which resulted in over a million deaths.2 This compares to 3.5 million women infected and around 500,000 who died from it.2  TB remains as one of the leading causes of death for ages 20-59 in both genders.2  It also presents significant risks to maternal health with a six-fold increase in perinatal deaths and a two-fold risk of premature birth for women infected with TB.2 
 It is widely thought that the risk of TB, in children is underestimated.2  In 2017, WHO estimated that almost one million children became infected with TB, which resulted in 250,000 deaths.2  Other contextual factors that increase risk of contracting TB are geography, poverty and poor health infrastructure 2  For example, the disease is endemic in developing countries and causes greater morbidity and mortality.2 The WHO estimated that in 2017, 95% of deaths occurred in developing countries, with 50% occurring in India, Pakistan, Indonesia, Philippines, and China.2 

2.4	PREVENTION AND CONTROL
WHO has adopted a total disease eradication program that envisions “a world free of TB.” 9  The End TB strategy, using the year 2015 as a baseline, aims to achieve a 95% reduction in TB deaths, 90% reduction in incidence, and to fully reduce ‘catastrophic costs’ for families affected by TB by the year 2035.9 End TB requires a multifaceted framework of relevant shareholders, advances in biomedicine, and cost control to achieve this ambitious target. 
The WHO states that early diagnosis of tuberculosis through drug-susceptibility testing is one of the most important tools in disease treatment.9 Focusing on patient-centered care and outcome, it recommends early screening for high-risk individuals, with a particular focus on immunocompromised individuals as well as other relevant comorbidities. Other prevention pillars include vaccination, spreading patient awareness and active monitoring through the Directly Observed, Short Term (DOTS) protocol to combat the spread of disease 9 
Reducing transmission of TB relies on applying control measures at healthcare facilities, with a particular focus on health care workers.10 These include administrative protocols that implement standard operating procedures based on sound infection control practices and include environmental controls such as isolation wards with negative air pressure to contain infectious respiratory droplets and using an appropriate personal protective equipment such as particulate respirators in situations where there is a high risk of transmissions.10 Household measures to reduce transmission involve isolating of suspected patients, practicing cough etiquette, and having ample ventilation i.e., a room where the volume of air entering or exiting a room is equal to the volume of the room.11
Prevention and control of TB disease on a population level require conducting surveillance through use of sentinel sites that have a reliable recording and reporting system in which various branches report to a central repository where data can be analyzed.11 The data can then be used to conduct assessments that focus on treatment outcomes in cohorts of patients, identifying high-risk areas and conducting quarterly evaluations for data verification and identifying performance problems.11  More than 200 countries have established a national TB program (NTP) that reports to the WHO Global TB Control to enhance monitoring of TB epidemics.9  The WHO releases yearly reports based on these compilations for analyzing global trends and comparing their impact and progress.  TB impact measurements focus on two components. The first component measures three ‘impact indicators’: incidence, prevalence and mortality.9 The second component focuses on conducting impact evaluation to measure if interventions to control TB have any effect on incidence, prevalence and mortality. 9	
Global TB eradication requires robust public health systems where collaboration and communication among various stakeholders is key to guiding policy options, funding biomedical advancements, and implementing the best practices that then can be disseminated to the community level.  
2.5	VACCINE CANDIDATES
The only TB vaccination that is currently licensed is the bacillus Calmette- Guerin (BCG) vaccine. It is a live, attenuated vaccine recommended and widely administered to infants in most areas endemic for TB, such as developing countries.13 It is effective for the prevention of various forms of EPTB such as tuberculosis meningitis and miliary tuberculosis. However, it is not effective in preventing adult PTB, which makes up most of the cases seen in the world. 
Currently, there is a push by small and large vaccine manufacturers to design a vaccine for TB that indirectly induces classical TH1 cytokines from effector T cells by acting through a large number of vectors, adjuvants, and antigens. According to recent reports, 16 candidate vaccines have progressed into clinical studies in the last 12 years.13 These candidate vaccines are formulated on a variety of vaccine approaches such as live, attenuated strains, whole cell vaccines, and DNA vaccines. Of these, two candidates, M72+AS01E [GlaxoSmithKline, Aeras] and M. Vaccae [Anhui ZhifeiLongcon, China] are in Phase IIb and Phase III clinical trials, respectively.13 Large-scale human clinical trials will be required to test efficacy and pass regulatory assessments. However, this renewed focus to develop a vaccine by a consortia of academia, industry and other experts is an encouraging step towards fulfilling the End TB targets put forth by WHO. 
2.6	INDIA SNAPSHOT
India has the highest TB burden in the world with an estimated incidence of 2.0-2.3 million TB cases and 150,000-350,000 deaths per year.2 The Indian health care infrastructure is burdened by a high population, therefore decreasing quality of care within the health care delivery system in the public and private sectors.12 This leads to problems in disease surveillance, clinical care, and monitoring.12 The government devised a national program called the Revised National Tuberculosis Control Program (RNTCP-2) to control the spread of TB, which was fully implemented in 2006.14A program was also initiated to address TB/HIV, MDR-TB, XDR-TB and to extend RNTCP to the private sector.14 Most TB patients registered by the RNTCP also receive HIV screening, and 90% of HIV positive TB patients are put on anti-retroviral treatment.14 In 2013, RNTCP achieved complete geographic coverage for diagnostic and treatment services for multi-drug resistant TB.14A total of 93,000 people with MDR-TB were diagnosed and given treatment for drug resistant TB by 2015.14
RNTCP has become one of the world’s largest public TB programs.14 A key goal is to provide free TB treatment to all Indians. It has established a network of laboratories and clinics throughout the country aided by a community health worker program to provide rapid testing and standardized treatment for TB. However, problems in disease surveillance and clinical care continue to be a concern due to lack of healthcare infrastructure in rural or tribal areas of the country. India had a budget of $280 million for TB in 2016, with funds from international NGO s making up for 62 percent of it.14
One factor contributing to the high incidence and mortality rate of TB in India is often a delay in diagnosis. On average, there is an estimated two month delay in making a diagnosis of TB with an average patient having to see around three different providers until a diagnosis is made.15  Delay in diagnosis is thought to be the leading contributor to the high mortality rate from TB, with India accounting for a third of all TB deaths in the world in 2016.2 Accurate diagnosis is hampered by lack of up to date equipment.16  The most common method for diagnosis used is two sputum smears taken at different times which are then analyzed under a microscope.16  This technique has a large margin of error and also takes much longer than modern machinery which can detect suspected TB samples quickly and with greater accuracy.16  After diagnosis, prescribing inappropriate anti-tuberculosis drug regimens compound the problem by lengthening cure to term, spreading drug resistance.16 
Lack of health awareness, particularly in low socioeconomic groups, contributes to India’s high TB burden.17  Persons with tuberculosis are often stigmatized by communities and many times choose to forgo treatment. This is particularly true among immunocompromised individuals who are HIV positive, migratory populations, and residents in large cities where overcrowding remains a persistent problem.17  Those who do seek treatment have to contend with health facilities that are understaffed and manned by poorly trained personnel.17  Many cases of TB are thought to be undetected as they may get treated as other respiratory diseases.17  Controlling resistance is further inhibited by availability of first-and second-line injectable over-the-counter drugs in pharmacies which leads to incorrect usage and further limits treatment options.17
As with all cases of TB, poor clinical case management in the public health infrastructure adds to the burden of resistant forms of TB. Overburdened by a large population, systemic  limitations prevent accurate detection rates across a swathe of public and private hospitals.17
2.7	SILICOSIS
A major confounding problem in treating MDR-TB is the presence of comorbidities like HIV, silicosis alcohol abuse, smoking and diabetes.25  These pose significant problems to control and treat TB, particularly in India.
Patients suffering from silicosis have a three-fold increased risk of TB infection.26  It has been estimated that more than 12 million workers working in mining and quartz industries are exposed to silica.26  Slate pencil industry and agate grinding industry have the highest risk of silicosis (54.6% and 38% respectively).26 Tuberculosis is observed in post mortem studies of industrial population occupationally exposed to high levels of silica.
2.8	HIV-AIDS
The HIV/AIDS pandemic pose a grave challenge to control TB. MDR-TB has been detected in about 6% of HIV seropositive cases while about 40% of seropositive HIV cases were also positive for and account for M. tuberculosis culture.27 India ranks third in the world for HIV-associated TB. It has been estimated that more than 120,000 HIV-positive TB cases have occurred in 2.1 million HIV-positive cases in India. It has been estimated that one of three TB-related deaths (29%) worldwide are probably due to HIV infection, while TB infection results in more than  26% of deaths due to HIV.28 About 2500–3000 HIV-infected persons develop MDR-TB annually in India.29
2.9	DIABETES MELLITUS (DM)




This paper has three aims:
	Examine prevalence of TB drug resistance amongst all TB cases presented to a large urban tertiary care hospital in Pune, India
	Document patterns in first and second line drug susceptibility for suspected MDR and XDR cases; and
	Inspect drug resistance in the two clinical manifestations of TB: pulmonary and extra pulmonary.
3.1	METHODS
A retrospective analysis was conducted at Deenanath Mangeshkar Hospital (DMH), Pune, from January 2015 to November 2016 for all patients who presented at the hospital for suspected TB. Limited clinical data were gathered to examine cases of pulmonary and extrapulmonary TB. Laboratory data were collected by extracting drug susceptibility testing (DST) information from the myco bacteriological laboratory. All laboratory data collected had been obtained by acid-fast bacilli tests via sputum or tissue. DST had been performed by the proportion method for testing resistance to first line drugs: Rifampicin(RIF), isoniazid(INH), ethambutol(EMB), streptomycin(STR); and second-line drugs: Fluoroquinolone(FQ), amikacin(Amk), kanamycin(KM) and Capreomycin(Cm).
4.0 	RESULTS
4.1	pune district
Pune, located in the western part of India, is the second largest city in the state of Maharashtra. With a population of five million it is one of the fastest growing cities in the Asia Pacific region. It has been estimated that 40% of the population lives in slums.  The Pune Municipal Corporation is the administrative unit of Pune district. One hundred and twenty three cases of MDR-TB were detected for the first time in Pune in 2012 at the referral laboratory at Aundh Chest Hospital, while six cases of XDR-TB were reported in 2013. MDR-TB claimed 49 lives in 2013.18 
4.2	DEENANATH MANGESHKAR HOSPITAL (DMH)
Deenanath Mangeshkar Hospital & Research Center,  a charitable, multi-specialty hospital located in the heart of Pune, was established in 2001.19  It is one of the largest hospitals in Pune, with 800 beds. The department of Infectious Diseases was started in 2003-04. It also serves as a tertiary care hospital for TB diagnosis and treatment for MDR-TB and non MDR-TB.19 
All suspected TB cases for the year 2015-2016 were recorded for patients who presented at DMH in Pune, India. There were over 703 suspected cases of TB, of which 205 were confirmed by DST screening. Of these, 54 (26.3%) were MDR-TB. Further screening for these MDR TB isolates showed XDR-TB in 32 isolates (59.2). The data gleaned at DMH were compared with a similar study by Pradhan et al. 19 conducted at Byramjee-Jeejeebhoy Medical College-Sassoon General Hospital  (BJMC-SGH) which is another tertiary care hospital in Pune (Table 1). 

Table 1: Summary of TB cases presented to Infectious disease ward at DMH and BJMC-SGH
	Total suspected	Total confirmed	MDR TB	XDR TB
DMH, Pune, IndiaYear 2015 to 2016	    703	205	 54 (26.3%)	32 (59.2% of total MDR cases)
BJMC, Pune, India Year 2008 to 2010 2	13,173	908	133 (14.6%)	 7 (5% of total MDR cases)*
* XDR-TB DST could only be ascertained in 2008
Deenanath Mangeshkar Hospital, Pune India and their comparison with similar data conducted by Pradhan et al. 201319 at Byramjee-Jeejeebhoy Medical College-Sassoon General Hospitals in Pune, India






Figure 1: First-line drug sensitivity patterns for suspected Multi-Drug Resistant tuberculosis cases presented at DMH and BJMC/SGH

Abbreviations: INH: Isoniazid; RIF: Rifampicin; EMB: Ethambutol; STR: Streptomycin; AMK : Amikacin; CIP: Ciprofloxacin; MDR-TB: Multidrug Resistant Tuberculosis(indicates resistance to at least INH and RIF)
Second-line injectable anti-tubercular drug resistance patterns for MDR-TB isolates (n=32) presented at DMH were as follows: out of 54 MDR-TB isolates presented, 32 were XDR-TB. Fifty percent of isolates were resistant FQ+KM, 28%  FQ+Amk, followed by 22% resistant to FQ+Cm (Figure 2). Data from the Pradhan et al. study20 were not shown as they were only able to test XDR susceptibility for FQ+Amk for one year. As a result, their data could not be sufficiently compared. 


Figure 2: Second line drug sensitivity patterns for extensively drug resistant tuberculosis cases presented to DMH 

Abbreviations: Fluroquinolones: FQ; KM: Kanamycin; Capreomycin ; XDR TB: Extensively Drug Resistant Tuberculosis(indicates resistant to isoniazid, rifampicin, fluoroquinolones, Kanamycin, Amikacin and Capreomycin 

All confirmed TB cases presented at DMH were classified according to the clinical manifestation diagnosed in the patient; Pulmonary TB or Extrapulmonary TB. There was a greater prevalence of PTB (55%) than EPTB (44%). Drug susceptibility testing showed an almost equal proportion of MDR and XDR TB in EPTB. Lastly, there was a higher proportion of XDR TB (19.7%) in EPTB than in PTB patients (12.8%) (Table 2).

Table 2: Differences observed in clinical manifestation of Tuberculosis and drug resistance for cases presented to Infectious Disease ward, DMH, 2015-2016

	Drug susceptible TB	  MDR-TB	  XDR-TB	
Pulmonary(PTB)	65 (57.0%)	35 (30.7%)	14 (12.8%)	114 (55.6%) of 205 confirmed cases of TB
Extra pulmonary(EPTB)	54 (59.3%)	19 (20.8%)	18 (19.7%)	91 (44.3%) of 205 confirmed cases of TB
5.0 	DISCUSSION
Standard anti-tubercular drug regimens lack efficacy in killing certain emerging strains of TB, having a devastating effect on global TB control. As described above, mutations in Mtb can lead to strains that are unaffected by antibiotics. They are then able to spread more successfully, which increases overall disease burden. Strains resistant to isoniazid and rifampicin are termed as multi-drug resistant (MDR-TB). Isoniazid and rifampicin, first-line anti-tubercular drugs, are commonly prescribed to treat suspected TB cases throughout the world. However, MDR-TB treatment requires using second-line TB drugs which are more expensive and cause harmful side effects, resulting in prolonged treatment. If bacteria develop resistance to these second-line drugs; the disease is untreatable. 
According to Figure 1, the findings at DMH compared with a similar study by Pradhan et al.19 at BJMC-SGH show a pattern of resistance to all first-line anti-tubercular drugs prescribed. Furthermore, though no comparative results are possible, the data at DMH showed parallel findings in potentially increasing drug resistance to second-line anti-tubercular drugs.  Defined as extensively-drug resistant TB (XDR-TB), these bacterial strains are resistant to at least rifampicin, isoniazid, and a second-line injectable drug. Both forms of drug resistant TB are prevalent in all parts of the world, but especially so in countries with poor health infrastructure. The lack of effective surveillance, monitoring and control causes drug resistance to spread rapidly in developing countries. The spread is further amplified by the high cost of first-and second-line anti-tubercular drugs, prescribing the incorrect drug and lack of adherence to treatment, which subsequently increase resistance in the bacteria, worsening disease burden. Drug resistant TB is growing in countries that are already suffering from a TB epidemic. For example, out of the almost 600 000 new cases of MDR-TB that were reported in 2016, almost half (47%) were from countries with the largest prevalence of TB (India, China, and the Russian
Federation).2
WHO, in 2015, estimated that out of 1,740,435 notified cases in India, 28,876 were MDR/RR-TB and 3,048 were XDR-TB, representing a significant global burden of drug resistant TB burden.2 In 2016, the WHO estimated that India accounted for 21% of MDR/RR TB in the world with over 40% of those being XDR-TB (Figure 1). The etiology of resistance to TB treatment is similar to that of drug susceptible TB. Babu et al. (2012)17 have three factors that increase drug resistant TB. These are 1) macro level community/health structure problems such as lack of awareness and non-adherence of patients to drug regimen; 2) substandard clinical and control services, and 3) improper usage of laboratory diagnostics and quality control.  
5.1	PUBLIC HEALTH SIGNIFICANCE
The estimated burden of MDR-TB cases in India is about 1.05 million (i.e. 2.1% of new cases and 13–17% of re-treatment cases are possibly MDR). The prevalence of MDR-TB among the treatment failures of new cases ranges from 17% to 41% and among re-treatment cases ranges from 32% to 86%.21  The emergence of MDR-TB, XDR-TB and TDR-TB (totally drug resistance tuberculosis) poses a grave challenge to controlling and eradicating TB globally and also economic growth.22  The numbers of MDR-TB and XDR-TB in EPTB cases are also a cause for concern. A recent study documented an increase in MDR-TB and XDR-TB and EPTB in pediatric TB cases. MDR-TB was detected in 28 (25.45%) patients, while 32 (29%) had pre-XDR-TB, and 9 (8.1%) patients had XDR-TB. 23
5.2	LIMITATIONS
Due to the time constrains and problems associated with obtaining relevant data from health departments, the study was restricted to a short period and confined to only one tertiary center. Due to a limited sample size, no statistically significant trends or prediction could be made. No information was available for comorbidity data or clinical outcome of either MDR-XDR-TB cases. However the prevalence of MDR-XDR-TB reported in this study is in line with other published surveys carried out on a larger sample and time period. Gathering epidemiological data from developing countries is challenging. Many officials, who were approached by the author  were reluctant to share data. Some officials insisted on a letter from the US embassy requesting data. One official even went to the extent of directing his staff to provide only data that would not reflect badly on his department. 
In view of the fact that India contributes to 25% of global TB burden, and increase in both MDR and XDR-TB cases, it was essential to study the problem. It was also very educational and informative to be able to talk with the community health workers, who are the backbone of TB control programs in India. The grave challenges faced by India to control TB can be gauged by the following sobering facts: A 300,000 children drop out of school because of a diagnosis of TB in the family. About 100,000 women are forced to leave their family after a TB diagnosis. It has been estimated that on an average two patients die of TB every five minutes. Between 2006 and 2014, the disease costs the Indian economy USD 340 billion.
6.0 	CONCLUSION
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